Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): An Eastern Cooperative Oncology Group study (E6501)

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 177-183

  Pillai, Rathi N ^a   Aisner, Joseph ^b   Dahlberg, Suzanne E ^c   Rogers, John S ^d   DiPaola, Robert S ^b   Aisner, Seena ^e   Ramalingam, Suresh S ^a   Schiller, Joan H ^f,g  

^a EMORY UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

^e University of Medicine and Dentistry of New Jersey   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

13 cis retinoic acid; Bcl 2; Interferon alpha; Small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; AMYLASE; ASPARTATE AMINOTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISOTRETINOIN; PACLITAXEL; PROTEIN BCL 2; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; COUGHING; DEHYDRATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPREGULATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, SMALL CELL; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COHORT STUDIES; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; LEUKOCYTES, MONONUCLEAR; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; SEVERITY OF ILLNESS INDEX; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS;

EID: 84903817586     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2427-7     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539-4544 (Pubitemid 46630948)
3. Ettinger DS, Aisner J (2006) Changing face of small-cell lung cancer: real and artifact. J Clin Oncol 24(28):4526-4527 (Pubitemid 46630944)
4. Abrams J, Doyle LA, Aisner J (1988) Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 15(3):261-277
5. Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H et al (1983) Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 67(1):37-43 (Pubitemid 13144172)
6. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R et al (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20(24):4665-4672 (Pubitemid 36025283)
7. Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P et al (2008) Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 99(3):442-447
8. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17(2):658-667 (Pubitemid 29075255)
9. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S et al (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10(8):1225-1229
10. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8(10):1613-1617 (Pubitemid 20334315)
11. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE (1998) A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77(2):347-351 (Pubitemid 28029555)
12. Cheng S, Evans WK, Stys-Norman D, Shepherd FA (2007) Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2(4):348-354 (Pubitemid 47181720)
13. Reed JC (1995) Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 82-83:155-158
14. McConkey DJ, Greene G, Pettaway CA (1996) Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56(24):5594-5599 (Pubitemid 26422158)
15. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC et al (1995) Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93(2):147-155
16. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT et al (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24):6940-6944 (Pubitemid 23006303)
17. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55(19):4438-4445
18. Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E et al (1996) Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 15(1):31-40 (Pubitemid 26337007)
19. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145(5):1036-1040 (Pubitemid 24345651)
20. Sartorius UA, Krammer PH (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97(5):584-592 (Pubitemid 34087795)
21. Smith MA, Parkinson DR, Cheson BD, Friedman MA (1992) Retinoids in cancer therapy. J Clin Oncol 10(5):839-864
22. Dahiya R, Boyle B, Park HD, Kurhanewicz J, Macdonald JM, Narayan P (1994) 13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells. Biochem Mol Biol Int 32(1):1-12 (Pubitemid 24077237)
23. Hu ZB, Minden MD, McCulloch EA (1996) Regulation of the synthesis of bcl-2 protein by growth factors. Leukemia 10(12):1925-1929 (Pubitemid 27019639)
24. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM et al (1992) 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235-241
25. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK et al (1992) 13-cisretinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84(4):241-245
26. DiPaola RS, Weiss RE, Cummings KB, Kong FM, Jirtle RL, Anscher M et al (1997) Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. Clin Cancer Res 3(11):1999-2004 (Pubitemid 27505126)
27. DiPaola RS, Aisner J (1999) Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 26(1 Suppl 2):112-116 (Pubitemid 29153693)
28. DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J et al (1999) Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 17(7):2213-2218 (Pubitemid 29318855)
29. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M et al (2008) Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26(6):870-876 (Pubitemid 351398078)
30. Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ et al (2011) A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 6(10):1757-1760
31. Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N et al (2011) A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 74(3):481-485
32. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163-3169